Removal of enzyme CK1α blocks cellular digestion in specific cancers. Credit: Dr. Jit Kong Cheong / Duke-NUS Graduate Medical School Singapore
A team of Singapore based scientists have found that pairing a new approach with an old drug may be an effective approach to treat common cancers. In a landmark study, Professor David Virshup and Dr. Jit Kong Cheong, from Duke-NUS Graduate Medical School Singapore (Duke-NUS), identified a new signalling pathway that regulates the internal diet of cancers.
Hitting this cellular nutritional pathway with a one-two punch stopped the growth of colon and bladder cancers, in experimental systems. The therapy used an old anti-malarial drug, combined with the inhibition of an enzyme called Casein Kinase 1 alpha (CK1α). This novel drug combination was uncovered because of the team's discovery of a feedback loop in cancer cells driven by a mutated gene, known as RAS and its regulation of CK1α.
The notorious RAS oncogene drives 30% of all human cancers in its mutated form. However, till now, scientists have found it difficult to directly target mutant RAS. Mutant RAS alters the cells' internal nutritional state via a process called autophagy.
The Duke-NUS team showed that mutant RAS controls autophagy via a Casein kinase 1α (CK1α)-dependent feedback loop. To sustain growth and stop cancer cells from self-cannibalism, mutant RAS makes lots of CK1α, a highly-active protein kinase. The research team found that CK1α is the Achilles heel of RAS-driven cancer cells.
A combination of CK1α blockade by the experimental drug D4476, and inhibition of autophagy by the anti-malarial chloroquine, was then tested and found able to effectively treat RAS-driven human colon and bladder tumours that were grown in laboratory mice.
"To our knowledge, this is the first report that shows the combined pharmacological targeting of CK1α and autophagy can be used to combat these types of cancer," said first author, Dr. Cheong. "Our findings provide the mechanistic basis of exploring combination therapies involving pharmacological targeting of CK1α and autophagy."
The team speculates that the new drug combination therapy could help to slow down or cure some human cancers with mutant RAS, such as those that originate from the colon and the bladder. They also infer that patients with pancreatic cancers and some lung cancers may benefit from this drug combination therapy, as the RAS oncogene is frequently mutated in these cancers.
"This is an exciting lead. We hope to identify more potent and specific inhibitors of CK1α to combine with autophagy inhibitors," said senior author Prof. Virshup, who is the Director of the Cancer and Stem Cell Biology Programme at Duke-NUS. "If these drug combination therapies are effective in rigorous clinical trials, it may be effective in patients with cancers that carry activating mutations of the RAS oncogene."
This study was published in The Journal of Clinical Investigation on 23 March 2015.
Explore further: Research reveals mechanism behind cell protein remodeling
Journal reference: Journal of Clinical Investigation
Provided by Duke-NUS Graduate Medical School Singapore
Medical Xpress on facebook
Related Stories
Research reveals mechanism behind cell protein remodeling
The remodeling of a kitchen or bathroom changes the appearance of the room and improves its functionality. As investigators at Rutgers Cancer Institute of New Jersey and Rutgers and Princeton Universities have demonstrated, ...
Weakness exposed in most common cancer gene
NYU Langone Medical Center researchers have found a biological weakness in the workings of the most commonly mutated gene involved in human cancers, known as mutant K-Ras, which they say can be exploited by drug chemotherapies ...
Discovery could lead to new drugs to stop many solid-tumor cancers
In a step forward in the battle against cancer, researchers have identified promising compounds to inhibit a key driver of many forms of the disease, including lung, prostate, colon, bladder and pancreatic cancer.
How NORE1A acts as a barrier to tumor growth
Researchers reveal how cells protect themselves from a protein that is a key driver of cancer. The study appears in The Journal of Cell Biology.
Study shows why some targeted cancer drugs lose effectiveness
A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to ...
Recommended for you
Detecting cancer cells in blood can give an early warning of treatment failure
A blood test that measures the number of cells shed from prostate tumours into the bloodstream can act as an early warning sign that treatment is not working, a major new study shows.
Stress granules ease the way for cancer metastasis
Tumors that produce more stress granules are more likely to metastasize, according to a study published in The Journal of Cell Biology. The results suggest that drugs to inhibit the formation of these struct ...
Sweeping prostate cancer review upends widely held belief on radiation after surgery
Important news for men receiving treatment for prostate cancer: Two new studies from the University of Virginia School of Medicine have upended the widely held view that it's best to delay radiation treatment ...
Research on small cellular changes may lead to big cancer solutions
Among cancers, scientists have spent their entire research careers looking for cellular similarities that may lead to a single cure for many cancers –– the rare chance to have a single answer to a multifaceted ...
Smokers at twice risk of prostate cancer recurring after surgery
Current smokers, and those who have quit smoking less than 10 years previously, have twice the risk of a recurrence of prostate cancer after surgery, according to new research presented at the European Association ...
The challenges of diagnosing cancers earlier: a GP's perspective
As GPs, we know that too many of our patients worry about wasting our time – a point underlined by a recent Cancer Research UK-funded study. ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
Removal of enzyme CK1α blocks cellular digestion in specific cancers. Credit: Dr. Jit Kong Cheong / Duke-NUS Graduate Medical School Singapore
A team of Singapore based scientists have found that pairing a new approach with an old drug may be an effective approach to treat common cancers. In a landmark study, Professor David Virshup and Dr. Jit Kong Cheong, from Duke-NUS Graduate Medical School Singapore (Duke-NUS), identified a new signalling pathway that regulates the internal diet of cancers.
Hitting this cellular nutritional pathway with a one-two punch stopped the growth of colon and bladder cancers, in experimental systems. The therapy used an old anti-malarial drug, combined with the inhibition of an enzyme called Casein Kinase 1 alpha (CK1α). This novel drug combination was uncovered because of the team's discovery of a feedback loop in cancer cells driven by a mutated gene, known as RAS and its regulation of CK1α.
The notorious RAS oncogene drives 30% of all human cancers in its mutated form. However, till now, scientists have found it difficult to directly target mutant RAS. Mutant RAS alters the cells' internal nutritional state via a process called autophagy.
The Duke-NUS team showed that mutant RAS controls autophagy via a Casein kinase 1α (CK1α)-dependent feedback loop. To sustain growth and stop cancer cells from self-cannibalism, mutant RAS makes lots of CK1α, a highly-active protein kinase. The research team found that CK1α is the Achilles heel of RAS-driven cancer cells.
A combination of CK1α blockade by the experimental drug D4476, and inhibition of autophagy by the anti-malarial chloroquine, was then tested and found able to effectively treat RAS-driven human colon and bladder tumours that were grown in laboratory mice.
"To our knowledge, this is the first report that shows the combined pharmacological targeting of CK1α and autophagy can be used to combat these types of cancer," said first author, Dr. Cheong. "Our findings provide the mechanistic basis of exploring combination therapies involving pharmacological targeting of CK1α and autophagy."
The team speculates that the new drug combination therapy could help to slow down or cure some human cancers with mutant RAS, such as those that originate from the colon and the bladder. They also infer that patients with pancreatic cancers and some lung cancers may benefit from this drug combination therapy, as the RAS oncogene is frequently mutated in these cancers.
"This is an exciting lead. We hope to identify more potent and specific inhibitors of CK1α to combine with autophagy inhibitors," said senior author Prof. Virshup, who is the Director of the Cancer and Stem Cell Biology Programme at Duke-NUS. "If these drug combination therapies are effective in rigorous clinical trials, it may be effective in patients with cancers that carry activating mutations of the RAS oncogene."
This study was published in The Journal of Clinical Investigation on 23 March 2015.
Explore further: Research reveals mechanism behind cell protein remodeling
Journal reference: Journal of Clinical Investigation
Provided by Duke-NUS Graduate Medical School Singapore
Medical Xpress on facebook
Related Stories
Research reveals mechanism behind cell protein remodeling
The remodeling of a kitchen or bathroom changes the appearance of the room and improves its functionality. As investigators at Rutgers Cancer Institute of New Jersey and Rutgers and Princeton Universities have demonstrated, ...
Weakness exposed in most common cancer gene
NYU Langone Medical Center researchers have found a biological weakness in the workings of the most commonly mutated gene involved in human cancers, known as mutant K-Ras, which they say can be exploited by drug chemotherapies ...
Discovery could lead to new drugs to stop many solid-tumor cancers
In a step forward in the battle against cancer, researchers have identified promising compounds to inhibit a key driver of many forms of the disease, including lung, prostate, colon, bladder and pancreatic cancer.
How NORE1A acts as a barrier to tumor growth
Researchers reveal how cells protect themselves from a protein that is a key driver of cancer. The study appears in The Journal of Cell Biology.
Study shows why some targeted cancer drugs lose effectiveness
A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to ...
Recommended for you
Detecting cancer cells in blood can give an early warning of treatment failure
A blood test that measures the number of cells shed from prostate tumours into the bloodstream can act as an early warning sign that treatment is not working, a major new study shows.
Stress granules ease the way for cancer metastasis
Tumors that produce more stress granules are more likely to metastasize, according to a study published in The Journal of Cell Biology. The results suggest that drugs to inhibit the formation of these struct ...
Sweeping prostate cancer review upends widely held belief on radiation after surgery
Important news for men receiving treatment for prostate cancer: Two new studies from the University of Virginia School of Medicine have upended the widely held view that it's best to delay radiation treatment ...
Research on small cellular changes may lead to big cancer solutions
Among cancers, scientists have spent their entire research careers looking for cellular similarities that may lead to a single cure for many cancers –– the rare chance to have a single answer to a multifaceted ...
Smokers at twice risk of prostate cancer recurring after surgery
Current smokers, and those who have quit smoking less than 10 years previously, have twice the risk of a recurrence of prostate cancer after surgery, according to new research presented at the European Association ...
The challenges of diagnosing cancers earlier: a GP's perspective
As GPs, we know that too many of our patients worry about wasting our time – a point underlined by a recent Cancer Research UK-funded study. ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
0 comments:
Post a Comment